EUCTR2015-002308-10-NL进行中（未招募）不适用
A randomized, single blinded trial to evaluate the efficacy of Imiquimod in women with residual/recurrent Cervical Intraepithelial Neoplasia (CIN) after previous treatment - TOPIC-2
未提供0 个研究点开始时间: 2015年7月9日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •- Histologically proven CIN2 or CIN 3, without invasion after previous surgical treatment at least 6 months before diagnosis
- •- Histologically proven persistent CIN 1 after previous surigcal treament at least 6 months before diagnosis. Persistent CIN 1 is defined as CIN 1 at least persistent for 6 months and proven with histology
- •- The patient is willing to use a medically acceptable method of contraception throughout the study
- •- Women older than 18 years of age
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 410
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Pregnancy or lactation
- •-(Micro-)invasive carcinoma
- •-Past history of cervical cancer
- •-Hypersensitivity of any components of the formulation
- •-History of psoriasis or other inflammatory dermatosis of the vulva
- •-Immunodeficiency or treatment with immunosuppressive medication
- •-Insufficient understanding of the Dutch or English language
研究者
相似试验
招募中
3 期
A randomized, single blinded trial to evaluate the efficacy of Imiquimod in women with residual/recurrent Cervical Intraepithelial Neoplasia (CIN) after previous treatmentCervical Intraepithelial NeoplasiaNL-OMON44944Erasmus MC, Universitair Medisch Centrum Rotterdam433
已完成
不适用
A trial of a very low calorie diet prior to cholecystectomy operation in obese patientsObesityISRCTN61630192orfolk and Norwich University Hospital (UK)46
进行中（未招募）
1 期
Efficacy and Safety of apraglutide in steroid refractory gastrointestinal acute graft versus host diseaseAcute graft versus host disease (aGVHD)MedDRA version: 20.0Level: PTClassification code 10075160Term: Graft versus host disease in gastrointestinal tractSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 20.0Level: LLTClassification code 10075161Term: Graft versus host disease in GI tractSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 20.1Level: PTClassification code 10066264Term: Acute graft versus host disease in intestineSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 20.1Level: PTClassification code 10066260Term: Acute graft versus host diseaseSystem Organ Class: 10021428 - Immune system disordersEUCTR2021-004588-29-DEVectivBio AG34
进行中（未招募）
1 期
Efficacy and Safety of apraglutide in steroid refractory gastrointestinal acute graft versus host diseaseEUCTR2021-004588-29-PTVectivBio AG34
进行中（未招募）
1 期
Efficacy and Safety of apraglutide in steroid refractory gastrointestinal acute graft versus host disease.Acute graft versus host disease (aGVHD)CTIS2023-507960-38-00VectivBio AG29